Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
The risks of multiple non-HIV medication prescriptions; PrEP use and sexually transmitted infection incidence; how vaginal bacteria relate to HIV seroconversion; the effect of early treatment on HIV in the brain.
Gauging treatment priority when CD4 count is high; the effect of hepatitis C coinfection on response to HIV treatment; HIV, aging and comorbidity in Africa; PrEP and drug-resistant gonorrhea.
Women with undetectable HIV viral loads when they received the first of three injections of Gardasil produced significantly more antibodies to HPV than women whose viral load was not undetectable.
A recent analysis investigated the relationship between HIV and syphilis -- specifically, to find out what syphilis infection may mean for people with HIV in terms of HIV viral load and risk of transmission.